Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099556 | 0.94 | RAB9A (0.75) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL8833182 | 0.88 | HDAC6 (0.62) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL15982289 | 0.86 | RAB9A (0.69) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL11900090 | 0.86 | HDAC6 (0.85) | RAB9AHDAC6HDAC2HDAC8LMNA | |
| SCHEMBL8833191 | 0.85 | HDAC6 (0.59) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL104773 | 0.84 | RAB9A (0.84) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL24934740 | 0.84 | RAB9A (0.76) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL18232439 | 0.84 | RAB9A (0.76) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL104476 | 0.84 | SMN1; SMN2 (0.76) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL10099559 | 0.84 | SMN1; SMN2 (0.76) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7432292-B2 | Sulfhydantoins as phosphate isosteres | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-07 | — | — | US | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | RAB9A 3030/4885SMN1; SMN2 4581/4885MEN1 3210/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | RAB9A 2803/4885SMN1; SMN2 4810/4885MEN1 3562/4885 |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | RAB9A 2803/4885SMN1; SMN2 4810/4885MEN1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.